Efficacy of NicVAX in Smokers Who Want to Quit Smoking

Completed · Phase 2 · Has a placebo group

Conditions studied: Smoking Cessation

In brief

The purpose of this study is to determine whether vaccination with NicVAX will result in a higher continuous abstinence rate than vaccination with placebo in smokers who want to quit smoking. In addition, two different formulations and dosing schedules will be studied, to select the dose and dosing schedule which generates the highest level of anti-nicotine antibodies. The primary study period is 12 months, which was extended by amendment to include up to 2 years of observations.

Key facts

Study ID
NCT00318383
Run by
National Institute on Drug Abuse (NIDA)
People needed
313
Starts
2006-05-01
Expected to finish
2007-12-01
Last updated by the study team
2017-01-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.